Acute tocolysis for uterine tachysystole or suspected fetal distress
Sebastian J Leathersich, Joshua P Vogel, Thach Son Tran, G Justus Hofmeyr, Sebastian J Leathersich, Joshua P Vogel, Thach Son Tran, G Justus Hofmeyr
Abstract
Background: Uterine tachysystole (more than 5 contractions per 10 minutes in 2 consecutive intervals) is common during labour, particularly with use of labour-stimulating agents. Tachysystole may reduce fetal oxygenation by interrupting maternal blood flow to the placenta during contractions. Reducing uterine contractions may improve placental blood flow, improving fetal oxygenation. This review aimed to evaluate the use of tocolytics to reduce or stop uterine contractions for improvement of the condition of the fetus in utero. This new review supersedes an earlier Cochrane Review on the same topic.
Objectives: To assess the effects of the use of acute tocolysis during labour for uterine tachysystole or suspected fetal distress, or both, on fetal, maternal and neonatal outcomes.
Search methods: We searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) (2 February 2018), and reference lists of retrieved studies.
Selection criteria: Randomised controlled trials (RCTs) evaluating acute tocolysis for uterine tachysystole, intrapartum fetal distress, or both.
Data collection and analysis: We used standard methods expected by Cochrane.
Main results: We included eight studies (734 women), conducted in hospital settings, predominantly in high-income countries (USA, Austria, Uruguay). Two trials were conducted in upper and lower middle-income countries (South Africa, Sri Lanka). The hospital facilities all had the capacity to perform caesarean section. Overall, the studies had a low risk of bias, except for methods to maintain blinding. All of the trials used a selective beta2 (ß2)-adrenergic agonist in one arm, however the drug used varied, as did the comparator. Limited information was available on maternal outcomes.Selective ß2-adrenergic agonist versus no tocolytic agent, whilst awaiting emergency deliveryThere were two stillbirths, both in the no tocolytic control group (risk ratio (RR) 0.23, 95% confidence interval (CI) 0.01 to 4.55; 2 studies, 57 women; low-quality evidence). One had gross hydrocephalus and the second occurred with vaginal delivery after waiting 55 minutes for caesarean section. The decision for caesarean section delivery was an inclusion criterion in both studies so we could not assess this as an outcome under this comparison. Abnormal fetal heart trace is probably lower with tocolytic treatment (RR 0.28, 95% CI 0.08 to 0.95; 2 studies, 43 women; moderate-quality evidence). The effects on the number of babies with Apgar score below seven were uncertain (low-quality evidence).Intravenous (IV) atosiban versus IV hexoprenaline (1 study, 26 women) One infant in the hexoprenaline group required > 24 hours in the neonatal intensive care unit (NICU) following a forceps delivery (RR 0.33, 95% CI 0.01 to 7.50; low-quality evidence). There were no fetal or neonatal mortalities and no Apgar scores below seven. There was one caesarean delivery in the IV hexoprenaline group (RR 0.33, 95% CI 0.01 to 7.50; low-quality evidence), and one case of abnormal fetal heart score in the atosiban group (RR 3.00, 95% CI 0.13 to 67.51; very low-quality evidence).IV fenoterol bromhydrate versus emergency delivery (1 study, 390 women) No data were reported for perinatal death, severe morbidity or fetal or neonatal mortality. IV fenoterol probably increases the risk of caesarean delivery (RR 1.12, 95% CI 1.04 to 1.22; moderate-quality evidence). Fenoterol may have little or no effect on the risk of Apgar scores below seven (RR 1.28, 95% CI 0.35 to 4.68; low-quality evidence).IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery (1 study, 37 women) No data were reported for perinatal death or severe morbidity. There were two fetal deaths in the no tocolytic control group (RR 0.23, 95% CI 0.01 to 4.55; low-quality evidence). The rate of caesarean delivery was not reported. There were two babies with Apgar scores below seven in the control group and none in the hexoprenaline group (RR 0.24, 95% CI 0.01 to 4.57; 35 women; low-quality evidence).Subcutaneous terbutaline versus IV magnesium sulphate (1 study, 46 women)No data were reported for perinatal death, severe morbidity or fetal or neonatal mortality. The decision for caesarean section was an inclusion criterion, so we could not assess this. The effects on abnormal fetal heart trace are uncertain (very low-quality evidence).Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic infusion without tocolytic agent (1 study, 28 women) No data were reported for perinatal death, severe morbidity or fetal or neonatal mortality. There may be little or no difference in the rates of caesarean delivery in the subcutaneous terbutaline (8/15) and control groups (4/13) (RR 1.73, 95% CI 0.68 to 4.45; low-quality evidence). There were no cases of Apgar scores below seven or abnormal fetal heart trace.Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery (1 study, 20 women) No data were reported for perinatal death or severe morbidity. There were no fetal or neonatal mortalities. The decision for caesarean section was an inclusion criterion, so we could not assess this. There were two babies with Apgar scores below seven in the control group and none in the terbutaline group (RR 0.17, 95% CI 0.01 to 3.08; low-quality evidence).IV terbutaline versus IV nitroglycerin (1 study, 110 women)No data were reported for perinatal death or severe morbidity or fetal or neonatal mortality. There may be little or no difference in the rates of caesarean delivery between the IV terbutaline (30/57) and control groups (29/53) (RR 0.96, 95% CI 0.68 to 1.36; low-quality evidence). There were no cases of Apgar scores below seven.
Authors' conclusions: There is insufficient evidence to determine the effects of tocolytics for uterine tachysystole or suspected fetal distress during labour. The clinical significance for some of the improvements in measures of fetal well-being with tocolytics is unclear. The sample sizes were too small to detect effects on neonatal morbidity, mortality or serious adverse effects. The majority of studies are from high-income countries in facilities with access to caesarean section, which may limit the generalisability of the results to lower-resource settings, or settings where caesarean section is not available.Further well-designed and adequately powered RCTs are required to evaluate clinically relevant indicators of maternal and neonatal morbidity and mortality.
Conflict of interest statement
Sebastian J Leathersich: none known. Joshua P Vogel: none known. Thach Son Tran: has received salary support from Garvan Institute of Medical Research since July 2014 G Justus Hofmeyr is an author of a trial included in the review (Kulier 1997). Decisions regarding inclusion of this trial were made by Sebastian Leathersich and Joshua Vogel.
Figures
![1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-AFig-FIG01.jpg)
![2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-AFig-FIG02.jpg)
![3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-AFig-FIG03.jpg)
![1.1. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-001-01.jpg)
![1.2. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-001-02.jpg)
1.3. Analysis
Comparison 1 Selective ß2‐adrenergic agonist…
1.3. Analysis
Comparison 1 Selective ß2‐adrenergic agonist versus no tocolytic agent, whilst awaiting emergency delivery,…
2.1. Analysis
Comparison 2 IV atosiban versus…
2.1. Analysis
Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 1 Perinatal death or severe…
2.2. Analysis
Comparison 2 IV atosiban versus…
2.2. Analysis
Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 2 Fetal or neonatal mortality.
2.3. Analysis
Comparison 2 IV atosiban versus…
2.3. Analysis
Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 3 Caesarean delivery.
2.4. Analysis
Comparison 2 IV atosiban versus…
2.4. Analysis
Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 4 Five‐minute Apgar score
2.5. Analysis
Comparison 2 IV atosiban versus…
2.5. Analysis
Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 5 Umbilical artery pH.
2.6. Analysis
Comparison 2 IV atosiban versus…
2.6. Analysis
Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 6 Abnormal fetal heart rate…
2.7. Analysis
Comparison 2 IV atosiban versus…
2.7. Analysis
Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 7 Maternal side effects (tachycardia…
2.8. Analysis
Comparison 2 IV atosiban versus…
2.8. Analysis
Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 8 Admission to NICU.
3.1. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.1. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 1 Caesarean delivery.
3.2. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.2. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 2 Five‐minute Apgar score…
3.3. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.3. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 3 Umbilical artery pH…
3.4. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.4. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 4 Umbilical cord blood…
3.5. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.5. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 5 Admission to NICU.
4.1. Analysis
Comparison 4 IV hexoprenaline versus…
4.1. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.2. Analysis
Comparison 4 IV hexoprenaline versus…
4.2. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.3. Analysis
Comparison 4 IV hexoprenaline versus…
4.3. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.4. Analysis
Comparison 4 IV hexoprenaline versus…
4.4. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.5. Analysis
Comparison 4 IV hexoprenaline versus…
4.5. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.6. Analysis
Comparison 4 IV hexoprenaline versus…
4.6. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.7. Analysis
Comparison 4 IV hexoprenaline versus…
4.7. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 1 Umbilical artery pH…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 2 Resolution of fetal…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
8.1. Analysis
Comparison 8 IV terbutaline versus…
8.1. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 1 Caesarean delivery.
8.2. Analysis
Comparison 8 IV terbutaline versus…
8.2. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 2 Five‐minute Apgar score
8.3. Analysis
Comparison 8 IV terbutaline versus…
8.3. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH
8.4. Analysis
Comparison 8 IV terbutaline versus…
8.4. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes…
8.5. Analysis
Comparison 8 IV terbutaline versus…
8.5. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose…
8.6. Analysis
Comparison 8 IV terbutaline versus…
8.6. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation.
8.7. Analysis
Comparison 8 IV terbutaline versus…
8.7. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid.
8.8. Analysis
Comparison 8 IV terbutaline versus…
8.8. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.
8.9. Analysis
Comparison 8 IV terbutaline versus…
8.9. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.
- doi: 10.1002/14651858.CD009770
- Combination of tocolytic agents for inhibiting preterm labour.Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Vogel JP, et al. Cochrane Database Syst Rev. 2014 Jul 11;(7):CD006169. doi: 10.1002/14651858.CD006169.pub2. Cochrane Database Syst Rev. 2014. PMID: 25010869 Review.
- Methods of term labour induction for women with a previous caesarean section.West HM, Jozwiak M, Dodd JM. West HM, et al. Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD009792. doi: 10.1002/14651858.CD009792.pub3. Cochrane Database Syst Rev. 2017. PMID: 28599068 Free PMC article. Review.
- Discontinuation of intravenous oxytocin in the active phase of induced labour.Boie S, Glavind J, Velu AV, Mol BWJ, Uldbjerg N, de Graaf I, Thornton JG, Bor P, Bakker JJ. Boie S, et al. Cochrane Database Syst Rev. 2018 Aug 20;8(8):CD012274. doi: 10.1002/14651858.CD012274.pub2. Cochrane Database Syst Rev. 2018. PMID: 30125998 Free PMC article. Review.
- Induction of labour at or beyond 37 weeks' gestation.Middleton P, Shepherd E, Morris J, Crowther CA, Gomersall JC. Middleton P, et al. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD004945. doi: 10.1002/14651858.CD004945.pub5. Cochrane Database Syst Rev. 2020. PMID: 32666584 Free PMC article.
- Oxytocin receptor antagonists for inhibiting preterm labour.Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Flenady V, et al. Cochrane Database Syst Rev. 2014 Jun 6;(6):CD004452. doi: 10.1002/14651858.CD004452.pub3. Cochrane Database Syst Rev. 2014. PMID: 24903678 Review.
- Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.Murata T, Kyozuka H, Yasuda S, Fukuda T, Tanaka T, Fujimori K. Murata T, et al. PLoS One. 2022 Mar 31;17(3):e0265872. doi: 10.1371/journal.pone.0265872. eCollection 2022. PLoS One. 2022. PMID: 35358222 Free PMC article.
- Terbutaline-triggered fetal arrhythmia prior to neonatal diagnosis of Wolff-Parkinson-White syndrome: A case report.Gross M, Iruretagoyena JI, Srinivasan S, Karnowski J, Adams J. Gross M, et al. Case Rep Womens Health. 2022 Jan 8;33:e00382. doi: 10.1016/j.crwh.2022.e00382. eCollection 2022 Jan. Case Rep Womens Health. 2022. PMID: 35070730 Free PMC article.
- Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Afonso Urich JA, et al. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597. Molecules. 2021. PMID: 34771005 Free PMC article.
- The Successful Use of Nitroglycerin for Uterine Hyperstimulation with Fetal Heart Rate Abnormality Caused by a Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS): A Case Report.Takakura S, Tanaka H, Enomoto N, Maki S, Ikeda T. Takakura S, et al. Medicina (Kaunas). 2021 May 12;57(5):478. doi: 10.3390/medicina57050478. Medicina (Kaunas). 2021. PMID: 34065827 Free PMC article.
- Changes in cAMP effector predominance are associated with increased oxytocin receptor expression in twin but not infection-associated or idiopathic preterm labour.Yulia A, Varley AJ, Singh N, Lei K, Tribe R, Johnson MR. Yulia A, et al. PLoS One. 2020 Nov 30;15(11):e0240325. doi: 10.1371/journal.pone.0240325. eCollection 2020. PLoS One. 2020. PMID: 33253216 Free PMC article.
- Meta-Analysis
- Research Support, Non-U.S. Gov't
- Review
- Systematic Review
- Adrenergic beta-2 Receptor Agonists / therapeutic use
- Cesarean Section / statistics & numerical data
- Female
- Fenoterol / therapeutic use
- Fetal Distress / drug therapy*
- Hexoprenaline / therapeutic use
- Humans
- Nitroglycerin / therapeutic use
- Perinatal Death
- Pregnancy
- Randomized Controlled Trials as Topic
- Terbutaline / therapeutic use
- Tocolysis / methods*
- Tocolytic Agents / therapeutic use*
- Uterine Contraction / drug effects*
- Vasotocin / analogs & derivatives
- Vasotocin / therapeutic use
- Adrenergic beta-2 Receptor Agonists
- Tocolytic Agents
- atosiban
- Fenoterol
- Nitroglycerin
- Hexoprenaline
- Terbutaline
- Vasotocin
- Full Text Sources
- Other Literature Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![1.3. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-001-03.jpg)
![2.1. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-002-01.jpg)
![2.2. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-002-02.jpg)
![2.3. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-002-03.jpg)
![2.4. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-002-04.jpg)
2.5. Analysis
Comparison 2 IV atosiban versus…
2.5. Analysis
Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 5 Umbilical artery pH.
2.6. Analysis
Comparison 2 IV atosiban versus…
2.6. Analysis
Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 6 Abnormal fetal heart rate…
2.7. Analysis
Comparison 2 IV atosiban versus…
2.7. Analysis
Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 7 Maternal side effects (tachycardia…
2.8. Analysis
Comparison 2 IV atosiban versus…
2.8. Analysis
Comparison 2 IV atosiban versus IV hexoprenaline, Outcome 8 Admission to NICU.
3.1. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.1. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 1 Caesarean delivery.
3.2. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.2. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 2 Five‐minute Apgar score…
3.3. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.3. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 3 Umbilical artery pH…
3.4. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.4. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 4 Umbilical cord blood…
3.5. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.5. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 5 Admission to NICU.
4.1. Analysis
Comparison 4 IV hexoprenaline versus…
4.1. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.2. Analysis
Comparison 4 IV hexoprenaline versus…
4.2. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.3. Analysis
Comparison 4 IV hexoprenaline versus…
4.3. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.4. Analysis
Comparison 4 IV hexoprenaline versus…
4.4. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.5. Analysis
Comparison 4 IV hexoprenaline versus…
4.5. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.6. Analysis
Comparison 4 IV hexoprenaline versus…
4.6. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.7. Analysis
Comparison 4 IV hexoprenaline versus…
4.7. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 1 Umbilical artery pH…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 2 Resolution of fetal…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
8.1. Analysis
Comparison 8 IV terbutaline versus…
8.1. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 1 Caesarean delivery.
8.2. Analysis
Comparison 8 IV terbutaline versus…
8.2. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 2 Five‐minute Apgar score
8.3. Analysis
Comparison 8 IV terbutaline versus…
8.3. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH
8.4. Analysis
Comparison 8 IV terbutaline versus…
8.4. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes…
8.5. Analysis
Comparison 8 IV terbutaline versus…
8.5. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose…
8.6. Analysis
Comparison 8 IV terbutaline versus…
8.6. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation.
8.7. Analysis
Comparison 8 IV terbutaline versus…
8.7. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid.
8.8. Analysis
Comparison 8 IV terbutaline versus…
8.8. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.
8.9. Analysis
Comparison 8 IV terbutaline versus…
8.9. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.
- doi: 10.1002/14651858.CD009770
- Combination of tocolytic agents for inhibiting preterm labour.Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Vogel JP, et al. Cochrane Database Syst Rev. 2014 Jul 11;(7):CD006169. doi: 10.1002/14651858.CD006169.pub2. Cochrane Database Syst Rev. 2014. PMID: 25010869 Review.
- Methods of term labour induction for women with a previous caesarean section.West HM, Jozwiak M, Dodd JM. West HM, et al. Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD009792. doi: 10.1002/14651858.CD009792.pub3. Cochrane Database Syst Rev. 2017. PMID: 28599068 Free PMC article. Review.
- Discontinuation of intravenous oxytocin in the active phase of induced labour.Boie S, Glavind J, Velu AV, Mol BWJ, Uldbjerg N, de Graaf I, Thornton JG, Bor P, Bakker JJ. Boie S, et al. Cochrane Database Syst Rev. 2018 Aug 20;8(8):CD012274. doi: 10.1002/14651858.CD012274.pub2. Cochrane Database Syst Rev. 2018. PMID: 30125998 Free PMC article. Review.
- Induction of labour at or beyond 37 weeks' gestation.Middleton P, Shepherd E, Morris J, Crowther CA, Gomersall JC. Middleton P, et al. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD004945. doi: 10.1002/14651858.CD004945.pub5. Cochrane Database Syst Rev. 2020. PMID: 32666584 Free PMC article.
- Oxytocin receptor antagonists for inhibiting preterm labour.Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Flenady V, et al. Cochrane Database Syst Rev. 2014 Jun 6;(6):CD004452. doi: 10.1002/14651858.CD004452.pub3. Cochrane Database Syst Rev. 2014. PMID: 24903678 Review.
- Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.Murata T, Kyozuka H, Yasuda S, Fukuda T, Tanaka T, Fujimori K. Murata T, et al. PLoS One. 2022 Mar 31;17(3):e0265872. doi: 10.1371/journal.pone.0265872. eCollection 2022. PLoS One. 2022. PMID: 35358222 Free PMC article.
- Terbutaline-triggered fetal arrhythmia prior to neonatal diagnosis of Wolff-Parkinson-White syndrome: A case report.Gross M, Iruretagoyena JI, Srinivasan S, Karnowski J, Adams J. Gross M, et al. Case Rep Womens Health. 2022 Jan 8;33:e00382. doi: 10.1016/j.crwh.2022.e00382. eCollection 2022 Jan. Case Rep Womens Health. 2022. PMID: 35070730 Free PMC article.
- Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Afonso Urich JA, et al. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597. Molecules. 2021. PMID: 34771005 Free PMC article.
- The Successful Use of Nitroglycerin for Uterine Hyperstimulation with Fetal Heart Rate Abnormality Caused by a Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS): A Case Report.Takakura S, Tanaka H, Enomoto N, Maki S, Ikeda T. Takakura S, et al. Medicina (Kaunas). 2021 May 12;57(5):478. doi: 10.3390/medicina57050478. Medicina (Kaunas). 2021. PMID: 34065827 Free PMC article.
- Changes in cAMP effector predominance are associated with increased oxytocin receptor expression in twin but not infection-associated or idiopathic preterm labour.Yulia A, Varley AJ, Singh N, Lei K, Tribe R, Johnson MR. Yulia A, et al. PLoS One. 2020 Nov 30;15(11):e0240325. doi: 10.1371/journal.pone.0240325. eCollection 2020. PLoS One. 2020. PMID: 33253216 Free PMC article.
- Meta-Analysis
- Research Support, Non-U.S. Gov't
- Review
- Systematic Review
- Adrenergic beta-2 Receptor Agonists / therapeutic use
- Cesarean Section / statistics & numerical data
- Female
- Fenoterol / therapeutic use
- Fetal Distress / drug therapy*
- Hexoprenaline / therapeutic use
- Humans
- Nitroglycerin / therapeutic use
- Perinatal Death
- Pregnancy
- Randomized Controlled Trials as Topic
- Terbutaline / therapeutic use
- Tocolysis / methods*
- Tocolytic Agents / therapeutic use*
- Uterine Contraction / drug effects*
- Vasotocin / analogs & derivatives
- Vasotocin / therapeutic use
- Adrenergic beta-2 Receptor Agonists
- Tocolytic Agents
- atosiban
- Fenoterol
- Nitroglycerin
- Hexoprenaline
- Terbutaline
- Vasotocin
- Full Text Sources
- Other Literature Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![2.5. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-002-05.jpg)
![2.6. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-002-06.jpg)
![2.7. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-002-07.jpg)
![2.8. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-002-08.jpg)
![3.1. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-003-01.jpg)
![3.2. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-003-02.jpg)
3.3. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.3. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 3 Umbilical artery pH…
3.4. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.4. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 4 Umbilical cord blood…
3.5. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.5. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 5 Admission to NICU.
4.1. Analysis
Comparison 4 IV hexoprenaline versus…
4.1. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.2. Analysis
Comparison 4 IV hexoprenaline versus…
4.2. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.3. Analysis
Comparison 4 IV hexoprenaline versus…
4.3. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.4. Analysis
Comparison 4 IV hexoprenaline versus…
4.4. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.5. Analysis
Comparison 4 IV hexoprenaline versus…
4.5. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.6. Analysis
Comparison 4 IV hexoprenaline versus…
4.6. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.7. Analysis
Comparison 4 IV hexoprenaline versus…
4.7. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 1 Umbilical artery pH…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 2 Resolution of fetal…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
8.1. Analysis
Comparison 8 IV terbutaline versus…
8.1. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 1 Caesarean delivery.
8.2. Analysis
Comparison 8 IV terbutaline versus…
8.2. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 2 Five‐minute Apgar score
8.3. Analysis
Comparison 8 IV terbutaline versus…
8.3. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH
8.4. Analysis
Comparison 8 IV terbutaline versus…
8.4. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes…
8.5. Analysis
Comparison 8 IV terbutaline versus…
8.5. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose…
8.6. Analysis
Comparison 8 IV terbutaline versus…
8.6. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation.
8.7. Analysis
Comparison 8 IV terbutaline versus…
8.7. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid.
8.8. Analysis
Comparison 8 IV terbutaline versus…
8.8. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.
8.9. Analysis
Comparison 8 IV terbutaline versus…
8.9. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.
- doi: 10.1002/14651858.CD009770
- Combination of tocolytic agents for inhibiting preterm labour.Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Vogel JP, et al. Cochrane Database Syst Rev. 2014 Jul 11;(7):CD006169. doi: 10.1002/14651858.CD006169.pub2. Cochrane Database Syst Rev. 2014. PMID: 25010869 Review.
- Methods of term labour induction for women with a previous caesarean section.West HM, Jozwiak M, Dodd JM. West HM, et al. Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD009792. doi: 10.1002/14651858.CD009792.pub3. Cochrane Database Syst Rev. 2017. PMID: 28599068 Free PMC article. Review.
- Discontinuation of intravenous oxytocin in the active phase of induced labour.Boie S, Glavind J, Velu AV, Mol BWJ, Uldbjerg N, de Graaf I, Thornton JG, Bor P, Bakker JJ. Boie S, et al. Cochrane Database Syst Rev. 2018 Aug 20;8(8):CD012274. doi: 10.1002/14651858.CD012274.pub2. Cochrane Database Syst Rev. 2018. PMID: 30125998 Free PMC article. Review.
- Induction of labour at or beyond 37 weeks' gestation.Middleton P, Shepherd E, Morris J, Crowther CA, Gomersall JC. Middleton P, et al. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD004945. doi: 10.1002/14651858.CD004945.pub5. Cochrane Database Syst Rev. 2020. PMID: 32666584 Free PMC article.
- Oxytocin receptor antagonists for inhibiting preterm labour.Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Flenady V, et al. Cochrane Database Syst Rev. 2014 Jun 6;(6):CD004452. doi: 10.1002/14651858.CD004452.pub3. Cochrane Database Syst Rev. 2014. PMID: 24903678 Review.
- Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.Murata T, Kyozuka H, Yasuda S, Fukuda T, Tanaka T, Fujimori K. Murata T, et al. PLoS One. 2022 Mar 31;17(3):e0265872. doi: 10.1371/journal.pone.0265872. eCollection 2022. PLoS One. 2022. PMID: 35358222 Free PMC article.
- Terbutaline-triggered fetal arrhythmia prior to neonatal diagnosis of Wolff-Parkinson-White syndrome: A case report.Gross M, Iruretagoyena JI, Srinivasan S, Karnowski J, Adams J. Gross M, et al. Case Rep Womens Health. 2022 Jan 8;33:e00382. doi: 10.1016/j.crwh.2022.e00382. eCollection 2022 Jan. Case Rep Womens Health. 2022. PMID: 35070730 Free PMC article.
- Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Afonso Urich JA, et al. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597. Molecules. 2021. PMID: 34771005 Free PMC article.
- The Successful Use of Nitroglycerin for Uterine Hyperstimulation with Fetal Heart Rate Abnormality Caused by a Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS): A Case Report.Takakura S, Tanaka H, Enomoto N, Maki S, Ikeda T. Takakura S, et al. Medicina (Kaunas). 2021 May 12;57(5):478. doi: 10.3390/medicina57050478. Medicina (Kaunas). 2021. PMID: 34065827 Free PMC article.
- Changes in cAMP effector predominance are associated with increased oxytocin receptor expression in twin but not infection-associated or idiopathic preterm labour.Yulia A, Varley AJ, Singh N, Lei K, Tribe R, Johnson MR. Yulia A, et al. PLoS One. 2020 Nov 30;15(11):e0240325. doi: 10.1371/journal.pone.0240325. eCollection 2020. PLoS One. 2020. PMID: 33253216 Free PMC article.
- Meta-Analysis
- Research Support, Non-U.S. Gov't
- Review
- Systematic Review
- Adrenergic beta-2 Receptor Agonists / therapeutic use
- Cesarean Section / statistics & numerical data
- Female
- Fenoterol / therapeutic use
- Fetal Distress / drug therapy*
- Hexoprenaline / therapeutic use
- Humans
- Nitroglycerin / therapeutic use
- Perinatal Death
- Pregnancy
- Randomized Controlled Trials as Topic
- Terbutaline / therapeutic use
- Tocolysis / methods*
- Tocolytic Agents / therapeutic use*
- Uterine Contraction / drug effects*
- Vasotocin / analogs & derivatives
- Vasotocin / therapeutic use
- Adrenergic beta-2 Receptor Agonists
- Tocolytic Agents
- atosiban
- Fenoterol
- Nitroglycerin
- Hexoprenaline
- Terbutaline
- Vasotocin
- Full Text Sources
- Other Literature Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![3.3. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-003-03.jpg)
3.4. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.4. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 4 Umbilical cord blood…
3.5. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.5. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 5 Admission to NICU.
4.1. Analysis
Comparison 4 IV hexoprenaline versus…
4.1. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.2. Analysis
Comparison 4 IV hexoprenaline versus…
4.2. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.3. Analysis
Comparison 4 IV hexoprenaline versus…
4.3. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.4. Analysis
Comparison 4 IV hexoprenaline versus…
4.4. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.5. Analysis
Comparison 4 IV hexoprenaline versus…
4.5. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.6. Analysis
Comparison 4 IV hexoprenaline versus…
4.6. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.7. Analysis
Comparison 4 IV hexoprenaline versus…
4.7. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 1 Umbilical artery pH…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 2 Resolution of fetal…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
8.1. Analysis
Comparison 8 IV terbutaline versus…
8.1. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 1 Caesarean delivery.
8.2. Analysis
Comparison 8 IV terbutaline versus…
8.2. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 2 Five‐minute Apgar score
8.3. Analysis
Comparison 8 IV terbutaline versus…
8.3. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH
8.4. Analysis
Comparison 8 IV terbutaline versus…
8.4. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes…
8.5. Analysis
Comparison 8 IV terbutaline versus…
8.5. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose…
8.6. Analysis
Comparison 8 IV terbutaline versus…
8.6. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation.
8.7. Analysis
Comparison 8 IV terbutaline versus…
8.7. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid.
8.8. Analysis
Comparison 8 IV terbutaline versus…
8.8. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.
8.9. Analysis
Comparison 8 IV terbutaline versus…
8.9. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.
- doi: 10.1002/14651858.CD009770
- Combination of tocolytic agents for inhibiting preterm labour.Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Vogel JP, et al. Cochrane Database Syst Rev. 2014 Jul 11;(7):CD006169. doi: 10.1002/14651858.CD006169.pub2. Cochrane Database Syst Rev. 2014. PMID: 25010869 Review.
- Methods of term labour induction for women with a previous caesarean section.West HM, Jozwiak M, Dodd JM. West HM, et al. Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD009792. doi: 10.1002/14651858.CD009792.pub3. Cochrane Database Syst Rev. 2017. PMID: 28599068 Free PMC article. Review.
- Discontinuation of intravenous oxytocin in the active phase of induced labour.Boie S, Glavind J, Velu AV, Mol BWJ, Uldbjerg N, de Graaf I, Thornton JG, Bor P, Bakker JJ. Boie S, et al. Cochrane Database Syst Rev. 2018 Aug 20;8(8):CD012274. doi: 10.1002/14651858.CD012274.pub2. Cochrane Database Syst Rev. 2018. PMID: 30125998 Free PMC article. Review.
- Induction of labour at or beyond 37 weeks' gestation.Middleton P, Shepherd E, Morris J, Crowther CA, Gomersall JC. Middleton P, et al. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD004945. doi: 10.1002/14651858.CD004945.pub5. Cochrane Database Syst Rev. 2020. PMID: 32666584 Free PMC article.
- Oxytocin receptor antagonists for inhibiting preterm labour.Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Flenady V, et al. Cochrane Database Syst Rev. 2014 Jun 6;(6):CD004452. doi: 10.1002/14651858.CD004452.pub3. Cochrane Database Syst Rev. 2014. PMID: 24903678 Review.
- Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.Murata T, Kyozuka H, Yasuda S, Fukuda T, Tanaka T, Fujimori K. Murata T, et al. PLoS One. 2022 Mar 31;17(3):e0265872. doi: 10.1371/journal.pone.0265872. eCollection 2022. PLoS One. 2022. PMID: 35358222 Free PMC article.
- Terbutaline-triggered fetal arrhythmia prior to neonatal diagnosis of Wolff-Parkinson-White syndrome: A case report.Gross M, Iruretagoyena JI, Srinivasan S, Karnowski J, Adams J. Gross M, et al. Case Rep Womens Health. 2022 Jan 8;33:e00382. doi: 10.1016/j.crwh.2022.e00382. eCollection 2022 Jan. Case Rep Womens Health. 2022. PMID: 35070730 Free PMC article.
- Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Afonso Urich JA, et al. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597. Molecules. 2021. PMID: 34771005 Free PMC article.
- The Successful Use of Nitroglycerin for Uterine Hyperstimulation with Fetal Heart Rate Abnormality Caused by a Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS): A Case Report.Takakura S, Tanaka H, Enomoto N, Maki S, Ikeda T. Takakura S, et al. Medicina (Kaunas). 2021 May 12;57(5):478. doi: 10.3390/medicina57050478. Medicina (Kaunas). 2021. PMID: 34065827 Free PMC article.
- Changes in cAMP effector predominance are associated with increased oxytocin receptor expression in twin but not infection-associated or idiopathic preterm labour.Yulia A, Varley AJ, Singh N, Lei K, Tribe R, Johnson MR. Yulia A, et al. PLoS One. 2020 Nov 30;15(11):e0240325. doi: 10.1371/journal.pone.0240325. eCollection 2020. PLoS One. 2020. PMID: 33253216 Free PMC article.
- Meta-Analysis
- Research Support, Non-U.S. Gov't
- Review
- Systematic Review
- Adrenergic beta-2 Receptor Agonists / therapeutic use
- Cesarean Section / statistics & numerical data
- Female
- Fenoterol / therapeutic use
- Fetal Distress / drug therapy*
- Hexoprenaline / therapeutic use
- Humans
- Nitroglycerin / therapeutic use
- Perinatal Death
- Pregnancy
- Randomized Controlled Trials as Topic
- Terbutaline / therapeutic use
- Tocolysis / methods*
- Tocolytic Agents / therapeutic use*
- Uterine Contraction / drug effects*
- Vasotocin / analogs & derivatives
- Vasotocin / therapeutic use
- Adrenergic beta-2 Receptor Agonists
- Tocolytic Agents
- atosiban
- Fenoterol
- Nitroglycerin
- Hexoprenaline
- Terbutaline
- Vasotocin
- Full Text Sources
- Other Literature Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![3.4. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-003-04.jpg)
3.5. Analysis
Comparison 3 IV fenoterol bromhydrate…
3.5. Analysis
Comparison 3 IV fenoterol bromhydrate versus emergency delivery, Outcome 5 Admission to NICU.
4.1. Analysis
Comparison 4 IV hexoprenaline versus…
4.1. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.2. Analysis
Comparison 4 IV hexoprenaline versus…
4.2. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.3. Analysis
Comparison 4 IV hexoprenaline versus…
4.3. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.4. Analysis
Comparison 4 IV hexoprenaline versus…
4.4. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.5. Analysis
Comparison 4 IV hexoprenaline versus…
4.5. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.6. Analysis
Comparison 4 IV hexoprenaline versus…
4.6. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.7. Analysis
Comparison 4 IV hexoprenaline versus…
4.7. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 1 Umbilical artery pH…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 2 Resolution of fetal…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
8.1. Analysis
Comparison 8 IV terbutaline versus…
8.1. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 1 Caesarean delivery.
8.2. Analysis
Comparison 8 IV terbutaline versus…
8.2. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 2 Five‐minute Apgar score
8.3. Analysis
Comparison 8 IV terbutaline versus…
8.3. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH
8.4. Analysis
Comparison 8 IV terbutaline versus…
8.4. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes…
8.5. Analysis
Comparison 8 IV terbutaline versus…
8.5. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose…
8.6. Analysis
Comparison 8 IV terbutaline versus…
8.6. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation.
8.7. Analysis
Comparison 8 IV terbutaline versus…
8.7. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid.
8.8. Analysis
Comparison 8 IV terbutaline versus…
8.8. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.
8.9. Analysis
Comparison 8 IV terbutaline versus…
8.9. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.
- doi: 10.1002/14651858.CD009770
- Combination of tocolytic agents for inhibiting preterm labour.Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Vogel JP, et al. Cochrane Database Syst Rev. 2014 Jul 11;(7):CD006169. doi: 10.1002/14651858.CD006169.pub2. Cochrane Database Syst Rev. 2014. PMID: 25010869 Review.
- Methods of term labour induction for women with a previous caesarean section.West HM, Jozwiak M, Dodd JM. West HM, et al. Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD009792. doi: 10.1002/14651858.CD009792.pub3. Cochrane Database Syst Rev. 2017. PMID: 28599068 Free PMC article. Review.
- Discontinuation of intravenous oxytocin in the active phase of induced labour.Boie S, Glavind J, Velu AV, Mol BWJ, Uldbjerg N, de Graaf I, Thornton JG, Bor P, Bakker JJ. Boie S, et al. Cochrane Database Syst Rev. 2018 Aug 20;8(8):CD012274. doi: 10.1002/14651858.CD012274.pub2. Cochrane Database Syst Rev. 2018. PMID: 30125998 Free PMC article. Review.
- Induction of labour at or beyond 37 weeks' gestation.Middleton P, Shepherd E, Morris J, Crowther CA, Gomersall JC. Middleton P, et al. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD004945. doi: 10.1002/14651858.CD004945.pub5. Cochrane Database Syst Rev. 2020. PMID: 32666584 Free PMC article.
- Oxytocin receptor antagonists for inhibiting preterm labour.Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Flenady V, et al. Cochrane Database Syst Rev. 2014 Jun 6;(6):CD004452. doi: 10.1002/14651858.CD004452.pub3. Cochrane Database Syst Rev. 2014. PMID: 24903678 Review.
- Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.Murata T, Kyozuka H, Yasuda S, Fukuda T, Tanaka T, Fujimori K. Murata T, et al. PLoS One. 2022 Mar 31;17(3):e0265872. doi: 10.1371/journal.pone.0265872. eCollection 2022. PLoS One. 2022. PMID: 35358222 Free PMC article.
- Terbutaline-triggered fetal arrhythmia prior to neonatal diagnosis of Wolff-Parkinson-White syndrome: A case report.Gross M, Iruretagoyena JI, Srinivasan S, Karnowski J, Adams J. Gross M, et al. Case Rep Womens Health. 2022 Jan 8;33:e00382. doi: 10.1016/j.crwh.2022.e00382. eCollection 2022 Jan. Case Rep Womens Health. 2022. PMID: 35070730 Free PMC article.
- Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Afonso Urich JA, et al. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597. Molecules. 2021. PMID: 34771005 Free PMC article.
- The Successful Use of Nitroglycerin for Uterine Hyperstimulation with Fetal Heart Rate Abnormality Caused by a Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS): A Case Report.Takakura S, Tanaka H, Enomoto N, Maki S, Ikeda T. Takakura S, et al. Medicina (Kaunas). 2021 May 12;57(5):478. doi: 10.3390/medicina57050478. Medicina (Kaunas). 2021. PMID: 34065827 Free PMC article.
- Changes in cAMP effector predominance are associated with increased oxytocin receptor expression in twin but not infection-associated or idiopathic preterm labour.Yulia A, Varley AJ, Singh N, Lei K, Tribe R, Johnson MR. Yulia A, et al. PLoS One. 2020 Nov 30;15(11):e0240325. doi: 10.1371/journal.pone.0240325. eCollection 2020. PLoS One. 2020. PMID: 33253216 Free PMC article.
- Meta-Analysis
- Research Support, Non-U.S. Gov't
- Review
- Systematic Review
- Adrenergic beta-2 Receptor Agonists / therapeutic use
- Cesarean Section / statistics & numerical data
- Female
- Fenoterol / therapeutic use
- Fetal Distress / drug therapy*
- Hexoprenaline / therapeutic use
- Humans
- Nitroglycerin / therapeutic use
- Perinatal Death
- Pregnancy
- Randomized Controlled Trials as Topic
- Terbutaline / therapeutic use
- Tocolysis / methods*
- Tocolytic Agents / therapeutic use*
- Uterine Contraction / drug effects*
- Vasotocin / analogs & derivatives
- Vasotocin / therapeutic use
- Adrenergic beta-2 Receptor Agonists
- Tocolytic Agents
- atosiban
- Fenoterol
- Nitroglycerin
- Hexoprenaline
- Terbutaline
- Vasotocin
- Full Text Sources
- Other Literature Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![3.5. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-003-05.jpg)
![4.1. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-004-01.jpg)
![4.2. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-004-02.jpg)
4.3. Analysis
Comparison 4 IV hexoprenaline versus…
4.3. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.4. Analysis
Comparison 4 IV hexoprenaline versus…
4.4. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.5. Analysis
Comparison 4 IV hexoprenaline versus…
4.5. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.6. Analysis
Comparison 4 IV hexoprenaline versus…
4.6. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.7. Analysis
Comparison 4 IV hexoprenaline versus…
4.7. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 1 Umbilical artery pH…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 2 Resolution of fetal…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
8.1. Analysis
Comparison 8 IV terbutaline versus…
8.1. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 1 Caesarean delivery.
8.2. Analysis
Comparison 8 IV terbutaline versus…
8.2. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 2 Five‐minute Apgar score
8.3. Analysis
Comparison 8 IV terbutaline versus…
8.3. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH
8.4. Analysis
Comparison 8 IV terbutaline versus…
8.4. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes…
8.5. Analysis
Comparison 8 IV terbutaline versus…
8.5. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose…
8.6. Analysis
Comparison 8 IV terbutaline versus…
8.6. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation.
8.7. Analysis
Comparison 8 IV terbutaline versus…
8.7. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid.
8.8. Analysis
Comparison 8 IV terbutaline versus…
8.8. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.
8.9. Analysis
Comparison 8 IV terbutaline versus…
8.9. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.
- doi: 10.1002/14651858.CD009770
- Combination of tocolytic agents for inhibiting preterm labour.Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Vogel JP, et al. Cochrane Database Syst Rev. 2014 Jul 11;(7):CD006169. doi: 10.1002/14651858.CD006169.pub2. Cochrane Database Syst Rev. 2014. PMID: 25010869 Review.
- Methods of term labour induction for women with a previous caesarean section.West HM, Jozwiak M, Dodd JM. West HM, et al. Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD009792. doi: 10.1002/14651858.CD009792.pub3. Cochrane Database Syst Rev. 2017. PMID: 28599068 Free PMC article. Review.
- Discontinuation of intravenous oxytocin in the active phase of induced labour.Boie S, Glavind J, Velu AV, Mol BWJ, Uldbjerg N, de Graaf I, Thornton JG, Bor P, Bakker JJ. Boie S, et al. Cochrane Database Syst Rev. 2018 Aug 20;8(8):CD012274. doi: 10.1002/14651858.CD012274.pub2. Cochrane Database Syst Rev. 2018. PMID: 30125998 Free PMC article. Review.
- Induction of labour at or beyond 37 weeks' gestation.Middleton P, Shepherd E, Morris J, Crowther CA, Gomersall JC. Middleton P, et al. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD004945. doi: 10.1002/14651858.CD004945.pub5. Cochrane Database Syst Rev. 2020. PMID: 32666584 Free PMC article.
- Oxytocin receptor antagonists for inhibiting preterm labour.Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Flenady V, et al. Cochrane Database Syst Rev. 2014 Jun 6;(6):CD004452. doi: 10.1002/14651858.CD004452.pub3. Cochrane Database Syst Rev. 2014. PMID: 24903678 Review.
- Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.Murata T, Kyozuka H, Yasuda S, Fukuda T, Tanaka T, Fujimori K. Murata T, et al. PLoS One. 2022 Mar 31;17(3):e0265872. doi: 10.1371/journal.pone.0265872. eCollection 2022. PLoS One. 2022. PMID: 35358222 Free PMC article.
- Terbutaline-triggered fetal arrhythmia prior to neonatal diagnosis of Wolff-Parkinson-White syndrome: A case report.Gross M, Iruretagoyena JI, Srinivasan S, Karnowski J, Adams J. Gross M, et al. Case Rep Womens Health. 2022 Jan 8;33:e00382. doi: 10.1016/j.crwh.2022.e00382. eCollection 2022 Jan. Case Rep Womens Health. 2022. PMID: 35070730 Free PMC article.
- Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Afonso Urich JA, et al. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597. Molecules. 2021. PMID: 34771005 Free PMC article.
- The Successful Use of Nitroglycerin for Uterine Hyperstimulation with Fetal Heart Rate Abnormality Caused by a Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS): A Case Report.Takakura S, Tanaka H, Enomoto N, Maki S, Ikeda T. Takakura S, et al. Medicina (Kaunas). 2021 May 12;57(5):478. doi: 10.3390/medicina57050478. Medicina (Kaunas). 2021. PMID: 34065827 Free PMC article.
- Changes in cAMP effector predominance are associated with increased oxytocin receptor expression in twin but not infection-associated or idiopathic preterm labour.Yulia A, Varley AJ, Singh N, Lei K, Tribe R, Johnson MR. Yulia A, et al. PLoS One. 2020 Nov 30;15(11):e0240325. doi: 10.1371/journal.pone.0240325. eCollection 2020. PLoS One. 2020. PMID: 33253216 Free PMC article.
- Meta-Analysis
- Research Support, Non-U.S. Gov't
- Review
- Systematic Review
- Adrenergic beta-2 Receptor Agonists / therapeutic use
- Cesarean Section / statistics & numerical data
- Female
- Fenoterol / therapeutic use
- Fetal Distress / drug therapy*
- Hexoprenaline / therapeutic use
- Humans
- Nitroglycerin / therapeutic use
- Perinatal Death
- Pregnancy
- Randomized Controlled Trials as Topic
- Terbutaline / therapeutic use
- Tocolysis / methods*
- Tocolytic Agents / therapeutic use*
- Uterine Contraction / drug effects*
- Vasotocin / analogs & derivatives
- Vasotocin / therapeutic use
- Adrenergic beta-2 Receptor Agonists
- Tocolytic Agents
- atosiban
- Fenoterol
- Nitroglycerin
- Hexoprenaline
- Terbutaline
- Vasotocin
- Full Text Sources
- Other Literature Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![4.3. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-004-03.jpg)
4.4. Analysis
Comparison 4 IV hexoprenaline versus…
4.4. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.5. Analysis
Comparison 4 IV hexoprenaline versus…
4.5. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.6. Analysis
Comparison 4 IV hexoprenaline versus…
4.6. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
4.7. Analysis
Comparison 4 IV hexoprenaline versus…
4.7. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 1 Umbilical artery pH…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 2 Resolution of fetal…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
8.1. Analysis
Comparison 8 IV terbutaline versus…
8.1. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 1 Caesarean delivery.
8.2. Analysis
Comparison 8 IV terbutaline versus…
8.2. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 2 Five‐minute Apgar score
8.3. Analysis
Comparison 8 IV terbutaline versus…
8.3. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH
8.4. Analysis
Comparison 8 IV terbutaline versus…
8.4. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes…
8.5. Analysis
Comparison 8 IV terbutaline versus…
8.5. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose…
8.6. Analysis
Comparison 8 IV terbutaline versus…
8.6. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation.
8.7. Analysis
Comparison 8 IV terbutaline versus…
8.7. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid.
8.8. Analysis
Comparison 8 IV terbutaline versus…
8.8. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.
8.9. Analysis
Comparison 8 IV terbutaline versus…
8.9. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.
- doi: 10.1002/14651858.CD009770
- Combination of tocolytic agents for inhibiting preterm labour.Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Vogel JP, et al. Cochrane Database Syst Rev. 2014 Jul 11;(7):CD006169. doi: 10.1002/14651858.CD006169.pub2. Cochrane Database Syst Rev. 2014. PMID: 25010869 Review.
- Methods of term labour induction for women with a previous caesarean section.West HM, Jozwiak M, Dodd JM. West HM, et al. Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD009792. doi: 10.1002/14651858.CD009792.pub3. Cochrane Database Syst Rev. 2017. PMID: 28599068 Free PMC article. Review.
- Discontinuation of intravenous oxytocin in the active phase of induced labour.Boie S, Glavind J, Velu AV, Mol BWJ, Uldbjerg N, de Graaf I, Thornton JG, Bor P, Bakker JJ. Boie S, et al. Cochrane Database Syst Rev. 2018 Aug 20;8(8):CD012274. doi: 10.1002/14651858.CD012274.pub2. Cochrane Database Syst Rev. 2018. PMID: 30125998 Free PMC article. Review.
- Induction of labour at or beyond 37 weeks' gestation.Middleton P, Shepherd E, Morris J, Crowther CA, Gomersall JC. Middleton P, et al. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD004945. doi: 10.1002/14651858.CD004945.pub5. Cochrane Database Syst Rev. 2020. PMID: 32666584 Free PMC article.
- Oxytocin receptor antagonists for inhibiting preterm labour.Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Flenady V, et al. Cochrane Database Syst Rev. 2014 Jun 6;(6):CD004452. doi: 10.1002/14651858.CD004452.pub3. Cochrane Database Syst Rev. 2014. PMID: 24903678 Review.
- Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.Murata T, Kyozuka H, Yasuda S, Fukuda T, Tanaka T, Fujimori K. Murata T, et al. PLoS One. 2022 Mar 31;17(3):e0265872. doi: 10.1371/journal.pone.0265872. eCollection 2022. PLoS One. 2022. PMID: 35358222 Free PMC article.
- Terbutaline-triggered fetal arrhythmia prior to neonatal diagnosis of Wolff-Parkinson-White syndrome: A case report.Gross M, Iruretagoyena JI, Srinivasan S, Karnowski J, Adams J. Gross M, et al. Case Rep Womens Health. 2022 Jan 8;33:e00382. doi: 10.1016/j.crwh.2022.e00382. eCollection 2022 Jan. Case Rep Womens Health. 2022. PMID: 35070730 Free PMC article.
- Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Afonso Urich JA, et al. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597. Molecules. 2021. PMID: 34771005 Free PMC article.
- The Successful Use of Nitroglycerin for Uterine Hyperstimulation with Fetal Heart Rate Abnormality Caused by a Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS): A Case Report.Takakura S, Tanaka H, Enomoto N, Maki S, Ikeda T. Takakura S, et al. Medicina (Kaunas). 2021 May 12;57(5):478. doi: 10.3390/medicina57050478. Medicina (Kaunas). 2021. PMID: 34065827 Free PMC article.
- Changes in cAMP effector predominance are associated with increased oxytocin receptor expression in twin but not infection-associated or idiopathic preterm labour.Yulia A, Varley AJ, Singh N, Lei K, Tribe R, Johnson MR. Yulia A, et al. PLoS One. 2020 Nov 30;15(11):e0240325. doi: 10.1371/journal.pone.0240325. eCollection 2020. PLoS One. 2020. PMID: 33253216 Free PMC article.
- Meta-Analysis
- Research Support, Non-U.S. Gov't
- Review
- Systematic Review
- Adrenergic beta-2 Receptor Agonists / therapeutic use
- Cesarean Section / statistics & numerical data
- Female
- Fenoterol / therapeutic use
- Fetal Distress / drug therapy*
- Hexoprenaline / therapeutic use
- Humans
- Nitroglycerin / therapeutic use
- Perinatal Death
- Pregnancy
- Randomized Controlled Trials as Topic
- Terbutaline / therapeutic use
- Tocolysis / methods*
- Tocolytic Agents / therapeutic use*
- Uterine Contraction / drug effects*
- Vasotocin / analogs & derivatives
- Vasotocin / therapeutic use
- Adrenergic beta-2 Receptor Agonists
- Tocolytic Agents
- atosiban
- Fenoterol
- Nitroglycerin
- Hexoprenaline
- Terbutaline
- Vasotocin
- Full Text Sources
- Other Literature Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![4.4. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-004-04.jpg)
![4.5. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-004-05.jpg)
![4.6. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-004-06.jpg)
4.7. Analysis
Comparison 4 IV hexoprenaline versus…
4.7. Analysis
Comparison 4 IV hexoprenaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.1. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 1 Umbilical artery pH…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 2 Resolution of fetal…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
8.1. Analysis
Comparison 8 IV terbutaline versus…
8.1. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 1 Caesarean delivery.
8.2. Analysis
Comparison 8 IV terbutaline versus…
8.2. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 2 Five‐minute Apgar score
8.3. Analysis
Comparison 8 IV terbutaline versus…
8.3. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH
8.4. Analysis
Comparison 8 IV terbutaline versus…
8.4. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes…
8.5. Analysis
Comparison 8 IV terbutaline versus…
8.5. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose…
8.6. Analysis
Comparison 8 IV terbutaline versus…
8.6. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation.
8.7. Analysis
Comparison 8 IV terbutaline versus…
8.7. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid.
8.8. Analysis
Comparison 8 IV terbutaline versus…
8.8. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.
8.9. Analysis
Comparison 8 IV terbutaline versus…
8.9. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.
- doi: 10.1002/14651858.CD009770
- Combination of tocolytic agents for inhibiting preterm labour.Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Vogel JP, et al. Cochrane Database Syst Rev. 2014 Jul 11;(7):CD006169. doi: 10.1002/14651858.CD006169.pub2. Cochrane Database Syst Rev. 2014. PMID: 25010869 Review.
- Methods of term labour induction for women with a previous caesarean section.West HM, Jozwiak M, Dodd JM. West HM, et al. Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD009792. doi: 10.1002/14651858.CD009792.pub3. Cochrane Database Syst Rev. 2017. PMID: 28599068 Free PMC article. Review.
- Discontinuation of intravenous oxytocin in the active phase of induced labour.Boie S, Glavind J, Velu AV, Mol BWJ, Uldbjerg N, de Graaf I, Thornton JG, Bor P, Bakker JJ. Boie S, et al. Cochrane Database Syst Rev. 2018 Aug 20;8(8):CD012274. doi: 10.1002/14651858.CD012274.pub2. Cochrane Database Syst Rev. 2018. PMID: 30125998 Free PMC article. Review.
- Induction of labour at or beyond 37 weeks' gestation.Middleton P, Shepherd E, Morris J, Crowther CA, Gomersall JC. Middleton P, et al. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD004945. doi: 10.1002/14651858.CD004945.pub5. Cochrane Database Syst Rev. 2020. PMID: 32666584 Free PMC article.
- Oxytocin receptor antagonists for inhibiting preterm labour.Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Flenady V, et al. Cochrane Database Syst Rev. 2014 Jun 6;(6):CD004452. doi: 10.1002/14651858.CD004452.pub3. Cochrane Database Syst Rev. 2014. PMID: 24903678 Review.
- Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.Murata T, Kyozuka H, Yasuda S, Fukuda T, Tanaka T, Fujimori K. Murata T, et al. PLoS One. 2022 Mar 31;17(3):e0265872. doi: 10.1371/journal.pone.0265872. eCollection 2022. PLoS One. 2022. PMID: 35358222 Free PMC article.
- Terbutaline-triggered fetal arrhythmia prior to neonatal diagnosis of Wolff-Parkinson-White syndrome: A case report.Gross M, Iruretagoyena JI, Srinivasan S, Karnowski J, Adams J. Gross M, et al. Case Rep Womens Health. 2022 Jan 8;33:e00382. doi: 10.1016/j.crwh.2022.e00382. eCollection 2022 Jan. Case Rep Womens Health. 2022. PMID: 35070730 Free PMC article.
- Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Afonso Urich JA, et al. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597. Molecules. 2021. PMID: 34771005 Free PMC article.
- The Successful Use of Nitroglycerin for Uterine Hyperstimulation with Fetal Heart Rate Abnormality Caused by a Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS): A Case Report.Takakura S, Tanaka H, Enomoto N, Maki S, Ikeda T. Takakura S, et al. Medicina (Kaunas). 2021 May 12;57(5):478. doi: 10.3390/medicina57050478. Medicina (Kaunas). 2021. PMID: 34065827 Free PMC article.
- Changes in cAMP effector predominance are associated with increased oxytocin receptor expression in twin but not infection-associated or idiopathic preterm labour.Yulia A, Varley AJ, Singh N, Lei K, Tribe R, Johnson MR. Yulia A, et al. PLoS One. 2020 Nov 30;15(11):e0240325. doi: 10.1371/journal.pone.0240325. eCollection 2020. PLoS One. 2020. PMID: 33253216 Free PMC article.
- Meta-Analysis
- Research Support, Non-U.S. Gov't
- Review
- Systematic Review
- Adrenergic beta-2 Receptor Agonists / therapeutic use
- Cesarean Section / statistics & numerical data
- Female
- Fenoterol / therapeutic use
- Fetal Distress / drug therapy*
- Hexoprenaline / therapeutic use
- Humans
- Nitroglycerin / therapeutic use
- Perinatal Death
- Pregnancy
- Randomized Controlled Trials as Topic
- Terbutaline / therapeutic use
- Tocolysis / methods*
- Tocolytic Agents / therapeutic use*
- Uterine Contraction / drug effects*
- Vasotocin / analogs & derivatives
- Vasotocin / therapeutic use
- Adrenergic beta-2 Receptor Agonists
- Tocolytic Agents
- atosiban
- Fenoterol
- Nitroglycerin
- Hexoprenaline
- Terbutaline
- Vasotocin
- Full Text Sources
- Other Literature Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![4.7. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-004-07.jpg)
![5.1. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-005-01.jpg)
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus…
5.2. Analysis
Comparison 5 Subcutaneous terbutaline versus IV magnesium sulphate, Outcome 2 Resolution of fetal…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.1. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.2. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
8.1. Analysis
Comparison 8 IV terbutaline versus…
8.1. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 1 Caesarean delivery.
8.2. Analysis
Comparison 8 IV terbutaline versus…
8.2. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 2 Five‐minute Apgar score
8.3. Analysis
Comparison 8 IV terbutaline versus…
8.3. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH
8.4. Analysis
Comparison 8 IV terbutaline versus…
8.4. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes…
8.5. Analysis
Comparison 8 IV terbutaline versus…
8.5. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose…
8.6. Analysis
Comparison 8 IV terbutaline versus…
8.6. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation.
8.7. Analysis
Comparison 8 IV terbutaline versus…
8.7. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid.
8.8. Analysis
Comparison 8 IV terbutaline versus…
8.8. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.
8.9. Analysis
Comparison 8 IV terbutaline versus…
8.9. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.
- doi: 10.1002/14651858.CD009770
- Combination of tocolytic agents for inhibiting preterm labour.Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Vogel JP, et al. Cochrane Database Syst Rev. 2014 Jul 11;(7):CD006169. doi: 10.1002/14651858.CD006169.pub2. Cochrane Database Syst Rev. 2014. PMID: 25010869 Review.
- Methods of term labour induction for women with a previous caesarean section.West HM, Jozwiak M, Dodd JM. West HM, et al. Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD009792. doi: 10.1002/14651858.CD009792.pub3. Cochrane Database Syst Rev. 2017. PMID: 28599068 Free PMC article. Review.
- Discontinuation of intravenous oxytocin in the active phase of induced labour.Boie S, Glavind J, Velu AV, Mol BWJ, Uldbjerg N, de Graaf I, Thornton JG, Bor P, Bakker JJ. Boie S, et al. Cochrane Database Syst Rev. 2018 Aug 20;8(8):CD012274. doi: 10.1002/14651858.CD012274.pub2. Cochrane Database Syst Rev. 2018. PMID: 30125998 Free PMC article. Review.
- Induction of labour at or beyond 37 weeks' gestation.Middleton P, Shepherd E, Morris J, Crowther CA, Gomersall JC. Middleton P, et al. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD004945. doi: 10.1002/14651858.CD004945.pub5. Cochrane Database Syst Rev. 2020. PMID: 32666584 Free PMC article.
- Oxytocin receptor antagonists for inhibiting preterm labour.Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Flenady V, et al. Cochrane Database Syst Rev. 2014 Jun 6;(6):CD004452. doi: 10.1002/14651858.CD004452.pub3. Cochrane Database Syst Rev. 2014. PMID: 24903678 Review.
- Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.Murata T, Kyozuka H, Yasuda S, Fukuda T, Tanaka T, Fujimori K. Murata T, et al. PLoS One. 2022 Mar 31;17(3):e0265872. doi: 10.1371/journal.pone.0265872. eCollection 2022. PLoS One. 2022. PMID: 35358222 Free PMC article.
- Terbutaline-triggered fetal arrhythmia prior to neonatal diagnosis of Wolff-Parkinson-White syndrome: A case report.Gross M, Iruretagoyena JI, Srinivasan S, Karnowski J, Adams J. Gross M, et al. Case Rep Womens Health. 2022 Jan 8;33:e00382. doi: 10.1016/j.crwh.2022.e00382. eCollection 2022 Jan. Case Rep Womens Health. 2022. PMID: 35070730 Free PMC article.
- Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Afonso Urich JA, et al. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597. Molecules. 2021. PMID: 34771005 Free PMC article.
- The Successful Use of Nitroglycerin for Uterine Hyperstimulation with Fetal Heart Rate Abnormality Caused by a Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS): A Case Report.Takakura S, Tanaka H, Enomoto N, Maki S, Ikeda T. Takakura S, et al. Medicina (Kaunas). 2021 May 12;57(5):478. doi: 10.3390/medicina57050478. Medicina (Kaunas). 2021. PMID: 34065827 Free PMC article.
- Changes in cAMP effector predominance are associated with increased oxytocin receptor expression in twin but not infection-associated or idiopathic preterm labour.Yulia A, Varley AJ, Singh N, Lei K, Tribe R, Johnson MR. Yulia A, et al. PLoS One. 2020 Nov 30;15(11):e0240325. doi: 10.1371/journal.pone.0240325. eCollection 2020. PLoS One. 2020. PMID: 33253216 Free PMC article.
- Meta-Analysis
- Research Support, Non-U.S. Gov't
- Review
- Systematic Review
- Adrenergic beta-2 Receptor Agonists / therapeutic use
- Cesarean Section / statistics & numerical data
- Female
- Fenoterol / therapeutic use
- Fetal Distress / drug therapy*
- Hexoprenaline / therapeutic use
- Humans
- Nitroglycerin / therapeutic use
- Perinatal Death
- Pregnancy
- Randomized Controlled Trials as Topic
- Terbutaline / therapeutic use
- Tocolysis / methods*
- Tocolytic Agents / therapeutic use*
- Uterine Contraction / drug effects*
- Vasotocin / analogs & derivatives
- Vasotocin / therapeutic use
- Adrenergic beta-2 Receptor Agonists
- Tocolytic Agents
- atosiban
- Fenoterol
- Nitroglycerin
- Hexoprenaline
- Terbutaline
- Vasotocin
- Full Text Sources
- Other Literature Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![5.2. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-005-02.jpg)
![6.1. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-006-01.jpg)
![6.2. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-006-02.jpg)
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.3. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
8.1. Analysis
Comparison 8 IV terbutaline versus…
8.1. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 1 Caesarean delivery.
8.2. Analysis
Comparison 8 IV terbutaline versus…
8.2. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 2 Five‐minute Apgar score
8.3. Analysis
Comparison 8 IV terbutaline versus…
8.3. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH
8.4. Analysis
Comparison 8 IV terbutaline versus…
8.4. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes…
8.5. Analysis
Comparison 8 IV terbutaline versus…
8.5. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose…
8.6. Analysis
Comparison 8 IV terbutaline versus…
8.6. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation.
8.7. Analysis
Comparison 8 IV terbutaline versus…
8.7. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid.
8.8. Analysis
Comparison 8 IV terbutaline versus…
8.8. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.
8.9. Analysis
Comparison 8 IV terbutaline versus…
8.9. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.
- doi: 10.1002/14651858.CD009770
- Combination of tocolytic agents for inhibiting preterm labour.Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Vogel JP, et al. Cochrane Database Syst Rev. 2014 Jul 11;(7):CD006169. doi: 10.1002/14651858.CD006169.pub2. Cochrane Database Syst Rev. 2014. PMID: 25010869 Review.
- Methods of term labour induction for women with a previous caesarean section.West HM, Jozwiak M, Dodd JM. West HM, et al. Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD009792. doi: 10.1002/14651858.CD009792.pub3. Cochrane Database Syst Rev. 2017. PMID: 28599068 Free PMC article. Review.
- Discontinuation of intravenous oxytocin in the active phase of induced labour.Boie S, Glavind J, Velu AV, Mol BWJ, Uldbjerg N, de Graaf I, Thornton JG, Bor P, Bakker JJ. Boie S, et al. Cochrane Database Syst Rev. 2018 Aug 20;8(8):CD012274. doi: 10.1002/14651858.CD012274.pub2. Cochrane Database Syst Rev. 2018. PMID: 30125998 Free PMC article. Review.
- Induction of labour at or beyond 37 weeks' gestation.Middleton P, Shepherd E, Morris J, Crowther CA, Gomersall JC. Middleton P, et al. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD004945. doi: 10.1002/14651858.CD004945.pub5. Cochrane Database Syst Rev. 2020. PMID: 32666584 Free PMC article.
- Oxytocin receptor antagonists for inhibiting preterm labour.Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Flenady V, et al. Cochrane Database Syst Rev. 2014 Jun 6;(6):CD004452. doi: 10.1002/14651858.CD004452.pub3. Cochrane Database Syst Rev. 2014. PMID: 24903678 Review.
- Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.Murata T, Kyozuka H, Yasuda S, Fukuda T, Tanaka T, Fujimori K. Murata T, et al. PLoS One. 2022 Mar 31;17(3):e0265872. doi: 10.1371/journal.pone.0265872. eCollection 2022. PLoS One. 2022. PMID: 35358222 Free PMC article.
- Terbutaline-triggered fetal arrhythmia prior to neonatal diagnosis of Wolff-Parkinson-White syndrome: A case report.Gross M, Iruretagoyena JI, Srinivasan S, Karnowski J, Adams J. Gross M, et al. Case Rep Womens Health. 2022 Jan 8;33:e00382. doi: 10.1016/j.crwh.2022.e00382. eCollection 2022 Jan. Case Rep Womens Health. 2022. PMID: 35070730 Free PMC article.
- Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Afonso Urich JA, et al. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597. Molecules. 2021. PMID: 34771005 Free PMC article.
- The Successful Use of Nitroglycerin for Uterine Hyperstimulation with Fetal Heart Rate Abnormality Caused by a Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS): A Case Report.Takakura S, Tanaka H, Enomoto N, Maki S, Ikeda T. Takakura S, et al. Medicina (Kaunas). 2021 May 12;57(5):478. doi: 10.3390/medicina57050478. Medicina (Kaunas). 2021. PMID: 34065827 Free PMC article.
- Changes in cAMP effector predominance are associated with increased oxytocin receptor expression in twin but not infection-associated or idiopathic preterm labour.Yulia A, Varley AJ, Singh N, Lei K, Tribe R, Johnson MR. Yulia A, et al. PLoS One. 2020 Nov 30;15(11):e0240325. doi: 10.1371/journal.pone.0240325. eCollection 2020. PLoS One. 2020. PMID: 33253216 Free PMC article.
- Meta-Analysis
- Research Support, Non-U.S. Gov't
- Review
- Systematic Review
- Adrenergic beta-2 Receptor Agonists / therapeutic use
- Cesarean Section / statistics & numerical data
- Female
- Fenoterol / therapeutic use
- Fetal Distress / drug therapy*
- Hexoprenaline / therapeutic use
- Humans
- Nitroglycerin / therapeutic use
- Perinatal Death
- Pregnancy
- Randomized Controlled Trials as Topic
- Terbutaline / therapeutic use
- Tocolysis / methods*
- Tocolytic Agents / therapeutic use*
- Uterine Contraction / drug effects*
- Vasotocin / analogs & derivatives
- Vasotocin / therapeutic use
- Adrenergic beta-2 Receptor Agonists
- Tocolytic Agents
- atosiban
- Fenoterol
- Nitroglycerin
- Hexoprenaline
- Terbutaline
- Vasotocin
- Full Text Sources
- Other Literature Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![6.3. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-006-03.jpg)
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.4. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with…
6.5. Analysis
Comparison 6 Subcutaneous terbutaline with continuation of oxytocic infusion versus cessation of oxytocic…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.1. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.2. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
8.1. Analysis
Comparison 8 IV terbutaline versus…
8.1. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 1 Caesarean delivery.
8.2. Analysis
Comparison 8 IV terbutaline versus…
8.2. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 2 Five‐minute Apgar score
8.3. Analysis
Comparison 8 IV terbutaline versus…
8.3. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH
8.4. Analysis
Comparison 8 IV terbutaline versus…
8.4. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes…
8.5. Analysis
Comparison 8 IV terbutaline versus…
8.5. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose…
8.6. Analysis
Comparison 8 IV terbutaline versus…
8.6. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation.
8.7. Analysis
Comparison 8 IV terbutaline versus…
8.7. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid.
8.8. Analysis
Comparison 8 IV terbutaline versus…
8.8. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.
8.9. Analysis
Comparison 8 IV terbutaline versus…
8.9. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.
- doi: 10.1002/14651858.CD009770
- Combination of tocolytic agents for inhibiting preterm labour.Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Vogel JP, et al. Cochrane Database Syst Rev. 2014 Jul 11;(7):CD006169. doi: 10.1002/14651858.CD006169.pub2. Cochrane Database Syst Rev. 2014. PMID: 25010869 Review.
- Methods of term labour induction for women with a previous caesarean section.West HM, Jozwiak M, Dodd JM. West HM, et al. Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD009792. doi: 10.1002/14651858.CD009792.pub3. Cochrane Database Syst Rev. 2017. PMID: 28599068 Free PMC article. Review.
- Discontinuation of intravenous oxytocin in the active phase of induced labour.Boie S, Glavind J, Velu AV, Mol BWJ, Uldbjerg N, de Graaf I, Thornton JG, Bor P, Bakker JJ. Boie S, et al. Cochrane Database Syst Rev. 2018 Aug 20;8(8):CD012274. doi: 10.1002/14651858.CD012274.pub2. Cochrane Database Syst Rev. 2018. PMID: 30125998 Free PMC article. Review.
- Induction of labour at or beyond 37 weeks' gestation.Middleton P, Shepherd E, Morris J, Crowther CA, Gomersall JC. Middleton P, et al. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD004945. doi: 10.1002/14651858.CD004945.pub5. Cochrane Database Syst Rev. 2020. PMID: 32666584 Free PMC article.
- Oxytocin receptor antagonists for inhibiting preterm labour.Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Flenady V, et al. Cochrane Database Syst Rev. 2014 Jun 6;(6):CD004452. doi: 10.1002/14651858.CD004452.pub3. Cochrane Database Syst Rev. 2014. PMID: 24903678 Review.
- Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.Murata T, Kyozuka H, Yasuda S, Fukuda T, Tanaka T, Fujimori K. Murata T, et al. PLoS One. 2022 Mar 31;17(3):e0265872. doi: 10.1371/journal.pone.0265872. eCollection 2022. PLoS One. 2022. PMID: 35358222 Free PMC article.
- Terbutaline-triggered fetal arrhythmia prior to neonatal diagnosis of Wolff-Parkinson-White syndrome: A case report.Gross M, Iruretagoyena JI, Srinivasan S, Karnowski J, Adams J. Gross M, et al. Case Rep Womens Health. 2022 Jan 8;33:e00382. doi: 10.1016/j.crwh.2022.e00382. eCollection 2022 Jan. Case Rep Womens Health. 2022. PMID: 35070730 Free PMC article.
- Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Afonso Urich JA, et al. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597. Molecules. 2021. PMID: 34771005 Free PMC article.
- The Successful Use of Nitroglycerin for Uterine Hyperstimulation with Fetal Heart Rate Abnormality Caused by a Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS): A Case Report.Takakura S, Tanaka H, Enomoto N, Maki S, Ikeda T. Takakura S, et al. Medicina (Kaunas). 2021 May 12;57(5):478. doi: 10.3390/medicina57050478. Medicina (Kaunas). 2021. PMID: 34065827 Free PMC article.
- Changes in cAMP effector predominance are associated with increased oxytocin receptor expression in twin but not infection-associated or idiopathic preterm labour.Yulia A, Varley AJ, Singh N, Lei K, Tribe R, Johnson MR. Yulia A, et al. PLoS One. 2020 Nov 30;15(11):e0240325. doi: 10.1371/journal.pone.0240325. eCollection 2020. PLoS One. 2020. PMID: 33253216 Free PMC article.
- Meta-Analysis
- Research Support, Non-U.S. Gov't
- Review
- Systematic Review
- Adrenergic beta-2 Receptor Agonists / therapeutic use
- Cesarean Section / statistics & numerical data
- Female
- Fenoterol / therapeutic use
- Fetal Distress / drug therapy*
- Hexoprenaline / therapeutic use
- Humans
- Nitroglycerin / therapeutic use
- Perinatal Death
- Pregnancy
- Randomized Controlled Trials as Topic
- Terbutaline / therapeutic use
- Tocolysis / methods*
- Tocolytic Agents / therapeutic use*
- Uterine Contraction / drug effects*
- Vasotocin / analogs & derivatives
- Vasotocin / therapeutic use
- Adrenergic beta-2 Receptor Agonists
- Tocolytic Agents
- atosiban
- Fenoterol
- Nitroglycerin
- Hexoprenaline
- Terbutaline
- Vasotocin
- Full Text Sources
- Other Literature Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![6.4. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-006-04.jpg)
![6.5. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-006-05.jpg)
![7.1. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-007-01.jpg)
![7.2. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-007-02.jpg)
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.3. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.4. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus…
7.5. Analysis
Comparison 7 Subcutaneous terbutaline versus no tocolytic agent, whilst awaiting emergency delivery, Outcome…
8.1. Analysis
Comparison 8 IV terbutaline versus…
8.1. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 1 Caesarean delivery.
8.2. Analysis
Comparison 8 IV terbutaline versus…
8.2. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 2 Five‐minute Apgar score
8.3. Analysis
Comparison 8 IV terbutaline versus…
8.3. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH
8.4. Analysis
Comparison 8 IV terbutaline versus…
8.4. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes…
8.5. Analysis
Comparison 8 IV terbutaline versus…
8.5. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose…
8.6. Analysis
Comparison 8 IV terbutaline versus…
8.6. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation.
8.7. Analysis
Comparison 8 IV terbutaline versus…
8.7. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid.
8.8. Analysis
Comparison 8 IV terbutaline versus…
8.8. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.
8.9. Analysis
Comparison 8 IV terbutaline versus…
8.9. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.
- doi: 10.1002/14651858.CD009770
- Combination of tocolytic agents for inhibiting preterm labour.Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Vogel JP, et al. Cochrane Database Syst Rev. 2014 Jul 11;(7):CD006169. doi: 10.1002/14651858.CD006169.pub2. Cochrane Database Syst Rev. 2014. PMID: 25010869 Review.
- Methods of term labour induction for women with a previous caesarean section.West HM, Jozwiak M, Dodd JM. West HM, et al. Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD009792. doi: 10.1002/14651858.CD009792.pub3. Cochrane Database Syst Rev. 2017. PMID: 28599068 Free PMC article. Review.
- Discontinuation of intravenous oxytocin in the active phase of induced labour.Boie S, Glavind J, Velu AV, Mol BWJ, Uldbjerg N, de Graaf I, Thornton JG, Bor P, Bakker JJ. Boie S, et al. Cochrane Database Syst Rev. 2018 Aug 20;8(8):CD012274. doi: 10.1002/14651858.CD012274.pub2. Cochrane Database Syst Rev. 2018. PMID: 30125998 Free PMC article. Review.
- Induction of labour at or beyond 37 weeks' gestation.Middleton P, Shepherd E, Morris J, Crowther CA, Gomersall JC. Middleton P, et al. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD004945. doi: 10.1002/14651858.CD004945.pub5. Cochrane Database Syst Rev. 2020. PMID: 32666584 Free PMC article.
- Oxytocin receptor antagonists for inhibiting preterm labour.Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Flenady V, et al. Cochrane Database Syst Rev. 2014 Jun 6;(6):CD004452. doi: 10.1002/14651858.CD004452.pub3. Cochrane Database Syst Rev. 2014. PMID: 24903678 Review.
- Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.Murata T, Kyozuka H, Yasuda S, Fukuda T, Tanaka T, Fujimori K. Murata T, et al. PLoS One. 2022 Mar 31;17(3):e0265872. doi: 10.1371/journal.pone.0265872. eCollection 2022. PLoS One. 2022. PMID: 35358222 Free PMC article.
- Terbutaline-triggered fetal arrhythmia prior to neonatal diagnosis of Wolff-Parkinson-White syndrome: A case report.Gross M, Iruretagoyena JI, Srinivasan S, Karnowski J, Adams J. Gross M, et al. Case Rep Womens Health. 2022 Jan 8;33:e00382. doi: 10.1016/j.crwh.2022.e00382. eCollection 2022 Jan. Case Rep Womens Health. 2022. PMID: 35070730 Free PMC article.
- Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Afonso Urich JA, et al. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597. Molecules. 2021. PMID: 34771005 Free PMC article.
- The Successful Use of Nitroglycerin for Uterine Hyperstimulation with Fetal Heart Rate Abnormality Caused by a Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS): A Case Report.Takakura S, Tanaka H, Enomoto N, Maki S, Ikeda T. Takakura S, et al. Medicina (Kaunas). 2021 May 12;57(5):478. doi: 10.3390/medicina57050478. Medicina (Kaunas). 2021. PMID: 34065827 Free PMC article.
- Changes in cAMP effector predominance are associated with increased oxytocin receptor expression in twin but not infection-associated or idiopathic preterm labour.Yulia A, Varley AJ, Singh N, Lei K, Tribe R, Johnson MR. Yulia A, et al. PLoS One. 2020 Nov 30;15(11):e0240325. doi: 10.1371/journal.pone.0240325. eCollection 2020. PLoS One. 2020. PMID: 33253216 Free PMC article.
- Meta-Analysis
- Research Support, Non-U.S. Gov't
- Review
- Systematic Review
- Adrenergic beta-2 Receptor Agonists / therapeutic use
- Cesarean Section / statistics & numerical data
- Female
- Fenoterol / therapeutic use
- Fetal Distress / drug therapy*
- Hexoprenaline / therapeutic use
- Humans
- Nitroglycerin / therapeutic use
- Perinatal Death
- Pregnancy
- Randomized Controlled Trials as Topic
- Terbutaline / therapeutic use
- Tocolysis / methods*
- Tocolytic Agents / therapeutic use*
- Uterine Contraction / drug effects*
- Vasotocin / analogs & derivatives
- Vasotocin / therapeutic use
- Adrenergic beta-2 Receptor Agonists
- Tocolytic Agents
- atosiban
- Fenoterol
- Nitroglycerin
- Hexoprenaline
- Terbutaline
- Vasotocin
- Full Text Sources
- Other Literature Sources
- Medical
NCBI Literature Resources
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
National Library of Medicine
8600 Rockville Pike
Bethesda, MD 20894
![7.3. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-007-03.jpg)
![7.4. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-007-04.jpg)
![7.5. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-007-05.jpg)
![8.1. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-008-01.jpg)
![8.2. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-008-02.jpg)
8.3. Analysis
Comparison 8 IV terbutaline versus…
8.3. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 3 Umbilical artery pH
8.4. Analysis
Comparison 8 IV terbutaline versus…
8.4. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes…
8.5. Analysis
Comparison 8 IV terbutaline versus…
8.5. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose…
8.6. Analysis
Comparison 8 IV terbutaline versus…
8.6. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation.
8.7. Analysis
Comparison 8 IV terbutaline versus…
8.7. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid.
8.8. Analysis
Comparison 8 IV terbutaline versus…
8.8. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.
8.9. Analysis
Comparison 8 IV terbutaline versus…
8.9. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.
- doi: 10.1002/14651858.CD009770
- Combination of tocolytic agents for inhibiting preterm labour.Vogel JP, Nardin JM, Dowswell T, West HM, Oladapo OT. Vogel JP, et al. Cochrane Database Syst Rev. 2014 Jul 11;(7):CD006169. doi: 10.1002/14651858.CD006169.pub2. Cochrane Database Syst Rev. 2014. PMID: 25010869 Review.
- Methods of term labour induction for women with a previous caesarean section.West HM, Jozwiak M, Dodd JM. West HM, et al. Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD009792. doi: 10.1002/14651858.CD009792.pub3. Cochrane Database Syst Rev. 2017. PMID: 28599068 Free PMC article. Review.
- Discontinuation of intravenous oxytocin in the active phase of induced labour.Boie S, Glavind J, Velu AV, Mol BWJ, Uldbjerg N, de Graaf I, Thornton JG, Bor P, Bakker JJ. Boie S, et al. Cochrane Database Syst Rev. 2018 Aug 20;8(8):CD012274. doi: 10.1002/14651858.CD012274.pub2. Cochrane Database Syst Rev. 2018. PMID: 30125998 Free PMC article. Review.
- Induction of labour at or beyond 37 weeks' gestation.Middleton P, Shepherd E, Morris J, Crowther CA, Gomersall JC. Middleton P, et al. Cochrane Database Syst Rev. 2020 Jul 15;7(7):CD004945. doi: 10.1002/14651858.CD004945.pub5. Cochrane Database Syst Rev. 2020. PMID: 32666584 Free PMC article.
- Oxytocin receptor antagonists for inhibiting preterm labour.Flenady V, Reinebrant HE, Liley HG, Tambimuttu EG, Papatsonis DN. Flenady V, et al. Cochrane Database Syst Rev. 2014 Jun 6;(6):CD004452. doi: 10.1002/14651858.CD004452.pub3. Cochrane Database Syst Rev. 2014. PMID: 24903678 Review.
- Effects of maternal ritodrine hydrochloride administration on the heart rate of preterm fetal sheep with intraamniotic inflammation.Murata T, Kyozuka H, Yasuda S, Fukuda T, Tanaka T, Fujimori K. Murata T, et al. PLoS One. 2022 Mar 31;17(3):e0265872. doi: 10.1371/journal.pone.0265872. eCollection 2022. PLoS One. 2022. PMID: 35358222 Free PMC article.
- Terbutaline-triggered fetal arrhythmia prior to neonatal diagnosis of Wolff-Parkinson-White syndrome: A case report.Gross M, Iruretagoyena JI, Srinivasan S, Karnowski J, Adams J. Gross M, et al. Case Rep Womens Health. 2022 Jan 8;33:e00382. doi: 10.1016/j.crwh.2022.e00382. eCollection 2022 Jan. Case Rep Womens Health. 2022. PMID: 35070730 Free PMC article.
- Development and Validation of a Stability-Indicating UPLC Method for the Determination of Hexoprenaline in Injectable Dosage Form Using AQbD Principles.Afonso Urich JA, Marko V, Boehm K, Lara García RA, Jeremic D, Paudel A. Afonso Urich JA, et al. Molecules. 2021 Oct 31;26(21):6597. doi: 10.3390/molecules26216597. Molecules. 2021. PMID: 34771005 Free PMC article.
- The Successful Use of Nitroglycerin for Uterine Hyperstimulation with Fetal Heart Rate Abnormality Caused by a Controlled-Release Dinoprostone Vaginal Delivery System (PROPESS): A Case Report.Takakura S, Tanaka H, Enomoto N, Maki S, Ikeda T. Takakura S, et al. Medicina (Kaunas). 2021 May 12;57(5):478. doi: 10.3390/medicina57050478. Medicina (Kaunas). 2021. PMID: 34065827 Free PMC article.
- Changes in cAMP effector predominance are associated with increased oxytocin receptor expression in twin but not infection-associated or idiopathic preterm labour.Yulia A, Varley AJ, Singh N, Lei K, Tribe R, Johnson MR. Yulia A, et al. PLoS One. 2020 Nov 30;15(11):e0240325. doi: 10.1371/journal.pone.0240325. eCollection 2020. PLoS One. 2020. PMID: 33253216 Free PMC article.
- Meta-Analysis
- Research Support, Non-U.S. Gov't
- Review
- Systematic Review
- Adrenergic beta-2 Receptor Agonists / therapeutic use
- Cesarean Section / statistics & numerical data
- Female
- Fenoterol / therapeutic use
- Fetal Distress / drug therapy*
- Hexoprenaline / therapeutic use
- Humans
- Nitroglycerin / therapeutic use
- Perinatal Death
- Pregnancy
- Randomized Controlled Trials as Topic
- Terbutaline / therapeutic use
- Tocolysis / methods*
- Tocolytic Agents / therapeutic use*
- Uterine Contraction / drug effects*
- Vasotocin / analogs & derivatives
- Vasotocin / therapeutic use
- Adrenergic beta-2 Receptor Agonists
- Tocolytic Agents
- atosiban
- Fenoterol
- Nitroglycerin
- Hexoprenaline
- Terbutaline
- Vasotocin
- Full Text Sources
- Other Literature Sources
- Medical
![8.3. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-008-03.jpg)
8.4. Analysis
Comparison 8 IV terbutaline versus…
8.4. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 4 Uterine tachysystole 10 minutes…
8.5. Analysis
Comparison 8 IV terbutaline versus…
8.5. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 5 Need for repeat dose…
8.6. Analysis
Comparison 8 IV terbutaline versus…
8.6. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 6 Successful fetal intrauterine resuscitation.
8.7. Analysis
Comparison 8 IV terbutaline versus…
8.7. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 7 Meconium‐stained amniotic fluid.
8.8. Analysis
Comparison 8 IV terbutaline versus…
8.8. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 8 Admission to NICU.
8.9. Analysis
Comparison 8 IV terbutaline versus…
8.9. Analysis
Comparison 8 IV terbutaline versus IV nitroglycerin, Outcome 9 Postpartum haemorrhage.
![8.4. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-008-04.jpg)
![8.5. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-008-05.jpg)
![8.6. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-008-06.jpg)
![8.7. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-008-07.jpg)
![8.8. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-008-08.jpg)
![8.9. Analysis](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6513259/bin/nCD009770-CMP-008-09.jpg)
Source: PubMed